Turkish Version of The Upper Limb Hypermobility Assessment Tool

Hypermobility is more than normal joint laxity, mobility, and range of motion. It is characterized by increased laxity and fragility of connective tissues. Symptoms from hypermobility can begin at any age and affect women more than men. People are at higher risk than other people. It is stated that hypermobility is an important factor in orthopedic injuries and diseases. Individuals with hypermobility have more frequent orthopedic complaints and the problems are usually idiopathic and chronic. Studies have reported that proprioception and musculoskeletal reflex function may be affected independently of symptoms in hypermobile individuals. Therefore, evaluating hypermobility is very important in preventing hypermobility-related problems and injuries and developing appropriate treatment methods. Although the Beighton score is the most commonly used scoring method to determine hypermobility, it may be insufficient to determine hypermobility of the upper extremities. The Upper Limb Hypermobility Assessment Tool (ULHAT) has been reported to be one of the most appropriate scoring methods for assessing upper extremity hypermobility in the literature. The aim of this study is to adapt ULHAT to Turkish and measure its validity and reliability.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypermobility, Joint Joint Diseases Joint Instability Musculoskeletal Diseases

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Kutahya Health Science University

Kütahya, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy volunteers
Aged between 18 to 35

Exclusion criteria

Using assistive devices or orthoses for the upper extremity
Surgery history of the upper extremity
Pain located on the upper extremity in the last 6 months
Previous trauma that might restrict normal range of motion.
Having degenerative or inflamatuar disease

Treatment and study plan

Turkish validity and reliability

Other

Explanation of the Turkish version of the scale.
Translating the Turkish version of the scale into English to ensure consistency with the original scale.
First application of scales to participants by two examiners separately.
Second application of the scales to the participants by one examiner.
Statistical analysis and scaling

Primary outcomes

The Upper Limb Hypermobility Assessment Tool (ULHAT)

Time frame: 15 minutes

The ULHAT was designed to test the mobility of many joints of the upper limb in multiple planes of motion. These tests include passive physiological, passive accessory and active range of motion.

The ULHAT is performed on both upper limbs, each providing a score to a maximum of 12.
The Beighton Score

Time frame: 5 minutes

The Beighton Score is a set of manoeuvres used as the standard method of assessment for Generalised Joint Hypermobility. The Beighton score arbitrarily investigates the presence of hyperlaxity (yes = 1, no = 0) at both wrists, the fifth metacarpo-phalangeal joints, elbows, knee joints, and the lumbosacral spine. The items are summed and yield a Beighton score ranging from 0 to 9 points.

Sponsors and collaborators

Lead sponsor

Kutahya Health Sciences University

Other

Registry information

Official study title

Turkish Version of The Upper Limb Hypermobility Assessment Tool : Reliability and Validity

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2022
First posted: Jun 28, 2022
Registry last updated: Nov 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed